Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Rhea-AI Summary
Haemonetics (NYSE: HAE) posted its third quarter fiscal 2026 results for the period ended December 27, 2025, on its Investor Relations website.
The company will host a conference call and live webcast at 8:00 a.m. ET on February 5, 2026, with a replay available from 11:00 a.m. ET on February 5, 2026 for one year. Earnings release and a supplemental presentation are posted and will be referenced on the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HAE declined 1.41%, reflecting a mild negative market reaction. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $41M from the company's valuation, bringing the market cap to $2.90B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HAE is up 1.68% while key medical device peers ATEC (-4.07%), INSP (-4.73%), ITGR (-0.66%), LIVN (-0.68%), and PRCT (-0.92%) are all down, indicating a stock-specific move around the earnings posting.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q2 FY26 earnings | Neutral | +32.3% | Second quarter FY26 results posted with webcast and replay details. |
| Aug 07 | Q1 FY26 earnings | Neutral | -26.6% | First quarter FY26 financial results posted and discussed via webcast. |
| May 08 | FY25 results | Neutral | +5.8% | Fourth quarter and full-year FY25 results with guidance materials released. |
| Feb 06 | Q3 FY25 earnings | Neutral | -11.6% | Third quarter FY25 results made available with investor call and replay. |
| Nov 07 | Q2 FY25 earnings | Neutral | +10.7% | Second quarter FY25 results posted with conference call and webcast. |
Earnings postings have historically driven large bidirectional moves, with reactions ranging from about -26.58% to +32.31%, indicating that quarterly updates have been important trading catalysts.
This announcement continues Haemonetics’ practice of posting full quarterly results and materials to its Investor Relations site and pairing them with an 8:00 a.m. ET call. Recent history includes the Vivasure Medical acquisition valued up to €185M, a J.P. Morgan Healthcare Conference presentation on Jan 13, 2026, and prior earnings releases such as Q2 FY26 on Nov 6, 2025, which saw a 32.31% move.
Historical Comparison
In the past five earnings-related releases, HAE’s average 24-hour move was 2.14%, with swings from -26.58% to +32.31%, showing that results often act as strong catalysts.
Earnings updates have consistently covered sequential quarters from FY2025 into FY2026, including Q2 and Q3 releases and full-year FY2025 results, highlighting a regular cadence of detailed financial communication.
Market Pulse Summary
This announcement directs investors to Haemonetics’ full third quarter FY2026 results and supplemental materials, plus an 8:00 a.m. ET call and one-year replay. Historically, similar earnings postings have produced sizable moves both up and down, such as +32.31% and -26.58%. Key items to watch in the materials include revenue trends, profitability, cash flow, and any updated guidance or portfolio commentary.
AI-generated analysis. Not financial advice.
Financial release and supplemental presentation accessible online
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026.
Conference Call and Webcast Information:
- Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended.
- Live webcast: Access here or through the Investor Relations section of the Haemonetics website.
A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on February 5, 2026 and will remain accessible for one year via the webcast link above.
Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:
- Third Quarter Fiscal 2026 Earnings Release
- Third Quarter Fiscal 2026 Supplemental Earnings Presentation
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-third-quarter-fiscal-2026-financial-results-available-on-investor-relations-website-302679292.html
SOURCE Haemonetics Corporation
FAQ
When did Haemonetics (HAE) report its third quarter fiscal 2026 results?
What time is the Haemonetics (HAE) Q3 2026 earnings conference call and webcast?
How can investors access the Haemonetics (HAE) earnings materials and webcast replay?
What materials did Haemonetics (HAE) post for Q3 fiscal 2026?
Do participants need to register to join the Haemonetics (HAE) Q3 earnings call?
